Unlearn Stock

unlearn.aiHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $135.17MM

Unlearn.AI is an AI healthcare company specializing in creating digital twins of patients to conduct clinical studies. Their technology aims to estimate the effects of therapy options for those affected by disease. Unlearn.AI was founded in 2017 by Charles Fisher Ph.D., Jonathan Walsh Ph.D., Aaron Smith Ph.D., and Graham Siegel JD and is headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Unlearn, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Unlearn’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Unlearn.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Charles Fisher Ph.D
Co-Founder, Chief Executive Officer & President
Aaron Smith Ph.D
Co-Founder, Machine Learning Scientist & Head of Machine Learning
Jonathan Walsh Ph.D
Co-Founder & Head of Modeling
Jack McGovern
Chief Financial Officer
Alex Lang Ph.D
Vice President of Technology

Board Members

Dylan Morris Ph.D
Insight Partners
Francisco Gimenez Ph.D
8VC
John Hamer Ph.D
DCVC
Alaa Halawa
Mubadala Capital Ventures
Eric Shiozaki Ph.D
DCVC Bio

Frequently Asked Questions About Unlearn’s Stock

plusminus
Can you buy Unlearn’s stock?
Unlearn is not publicly traded on NYSE or NASDAQ in the U.S. To buy Unlearn’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Unlearn’s stock?
Yes, you can sell stock of a private company like Unlearn. Forge can help you sell your Unlearn stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Unlearn’s stock price?
Unlearn is a privately held company and therefore does not have a public stock price. However, you may access Unlearn’s private market stock price with Forge Data.
plusminus
What is Unlearn’s stock ticker symbol?
Unlearn does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Unlearn Raises $50 Million Series C to Optimize Clinical Research With AI-Powered Digital Twin Technology
Unlearn, an AI company creating digital twins of clinical trial participants that enable smaller, faster studies, today announced a $50M Series C round led by Altimeter Capital, joined by returning investors Radical Ventures, Wittington Ventures, Mubadala Capital, Epic Ventures, and Necessary Venture Capital.
Digital twin developer Unlearn sees double with 2nd $50M venture capital round
Unlearn seems to have retained a lesson or two about fundraising: The digital twin developer announced this week that it has raised another $50 million, echoing its last funding round two years ago. The series C was led by Altimeter Capital, with additional support from many of the backers that had previously joined in on Unlearn’s early 2022 series B round, including that round’s leader, Insight Partners, as well as 8VC, DCVC and DCVC Bio, among others.
Biotech AI startup Unlearn adds $15 mln and OpenAI CTO to board
Unlearn.AI, which has built a machine learning platform that creates "digital twin" profiles of patients in clinical trials, has raised $15 million to expand partnerships and accelerate regulatory approval, the company told Reuters on Tuesday.
Updated on: May 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.